Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Buy" from Analysts

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $13.00.

HUMA has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. Benchmark reaffirmed a "buy" rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research report on Thursday, November 21st. BTIG Research reaffirmed a "buy" rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Finally, HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Humacyte in a research note on Wednesday, November 13th.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the firm's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last three months. 11.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HUMA. Renaissance Technologies LLC boosted its stake in shares of Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock valued at $2,881,000 after buying an additional 524,600 shares during the period. Thrivent Financial for Lutherans bought a new position in Humacyte during the 3rd quarter worth $712,000. Millennium Management LLC raised its holdings in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company's stock valued at $7,677,000 after acquiring an additional 1,334,641 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company's stock valued at $1,219,000 after acquiring an additional 97,931 shares during the period. Finally, AQR Capital Management LLC grew its holdings in shares of Humacyte by 1,018.4% during the 2nd quarter. AQR Capital Management LLC now owns 256,342 shares of the company's stock worth $1,230,000 after purchasing an additional 233,422 shares in the last quarter. 44.71% of the stock is owned by institutional investors.

Humacyte Stock Down 2.3 %

Shares of NASDAQ:HUMA traded down $0.08 during midday trading on Thursday, reaching $3.46. The company had a trading volume of 2,827,633 shares, compared to its average volume of 2,439,224. Humacyte has a 1-year low of $2.48 and a 1-year high of $9.97. The stock has a market cap of $435.47 million, a PE ratio of -2.58 and a beta of 1.38. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The business's 50 day moving average price is $4.85 and its 200 day moving average price is $5.87.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.